Autolus Therapeutics (NASDAQ:AUTL) Trading Up 7.4% – Still a Buy?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) shot up 7.4% on Wednesday . The stock traded as high as $1.93 and last traded at $1.97. 144,510 shares traded hands during trading, a decline of 88% from the average session volume of 1,187,248 shares. The stock had previously closed at $1.83.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, November 15th. Finally, The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Stock Up 11.7 %

The company has a market cap of $544.16 million, a price-to-earnings ratio of -1.69 and a beta of 2.07. The company has a 50 day moving average price of $2.15 and a 200-day moving average price of $3.09.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of AUTL. Wellington Management Group LLP lifted its holdings in shares of Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after purchasing an additional 6,330,392 shares in the last quarter. FMR LLC raised its stake in shares of Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after purchasing an additional 5,478,706 shares during the period. Candriam S.C.A. purchased a new stake in shares of Autolus Therapeutics in the fourth quarter worth about $7,500,000. AXA S.A. purchased a new position in Autolus Therapeutics during the fourth quarter valued at approximately $4,288,000. Finally, Millennium Management LLC increased its holdings in Autolus Therapeutics by 91.6% during the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company’s stock worth $3,885,000 after acquiring an additional 790,437 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.